Licensing Patented Innovations: Navigating International Markets and Regulations

India’s innovation landscape has grown considerably over the last two decades. Indian companies and research institutions are no longer just recipients of technology from the West – they are increasingly generating patented know-how that developed countries want access to. But taking that patented technology across borders, particularly to markets in the US, Europe, or Japan, is not simply a matter of signing a deal. It involves navigating intellectual property laws in foreign jurisdictions, export control regimes, regulatory compliance requirements, and hard-nosed commercial negotiations. This post breaks down what licensing patented know-how to clients in developed countries actually involves – and what an Indian licensor needs to get right.

What is meant by “licensing patented know-how”? 🔗

A patent gives its owner exclusive rights over an invention. Licensing is the mechanism by which those rights are permitted to be exercised by another party – the licensee – under agreed conditions, without transferring ownership. As noted by S&A Law Offices, licensing goes beyond mere information exchange. It includes the transfer of skills, manufacturing techniques, physical assets, and other technical aspects – what is collectively called know-how.

Know-how often travels alongside a patent because a patent document alone may not give the licensee sufficient practical guidance to actually use the invention. The licensee needs the underlying technical expertise – documented processes, operational data, formulation details – to truly exploit the patented technology. When this package of rights (patent + know-how) is licensed to clients in developed countries, the stakes and complexity both go up significantly.

Why target developed countries? 🔗

Developed markets – the US, EU member states, Japan, South Korea, and Australia – are attractive licensing destinations for a few reasons. They offer larger market sizes, stronger IP enforcement mechanisms, and higher royalty-paying capacity. As highlighted in IP licensing research, companies like Qualcomm generate a substantial share of their revenues purely from licensing their patent portfolios to manufacturers worldwide. The model is proven.

For Indian innovators, particularly in sectors like pharmaceuticals, software, advanced materials, and clean energy, developed-country clients represent partners who can commercialise innovations at a scale that domestic markets may not yet support. However, entering these markets requires deliberate preparation – both legally and commercially.

Securing patent protection in target markets first 🔗

Before approaching any client in a developed country, the foundational requirement is to hold a valid patent in that country. A patent granted by the Indian Patent Office under the Patents Act, 1970 only provides protection within Indian territory. To license technology in the US, you need a US patent. To license in Germany, you need European patent coverage.

The most efficient route for Indian inventors is the Patent Cooperation Treaty (PCT), administered by WIPO. By filing a single PCT application, an Indian applicant can simultaneously seek patent protection across over 150 contracting states. The PCT does not itself grant patents – it channels the application into national phase proceedings in each target country – but it substantially reduces the administrative and cost burden of filing separately in each jurisdiction. Indian residents must obtain a Foreign Filing Licence (FFL) from the Indian Patent Office before filing abroad, as required under Section 39 of the Patents Act, 1970. Filing without this clearance is a criminal offence under Indian law.

Once national phase entries are filed, the licensor should track prosecution timelines carefully. Approaching a potential licensee with a pending application is common and acceptable, but concluded licensing terms ideally take effect only after patent grant in the relevant jurisdiction.

Understanding export controls 🔗

One of the most underappreciated complexities in cross-border patent licensing is export control law. This is especially relevant when the licensee is in the US or an allied country. Export controls regulate not just the physical shipment of goods but also the transfer of technology and technical data across borders – including through email, training sessions, or technical documentation shared with foreign personnel.

In the US, two key regulatory frameworks apply: the Export Administration Regulations (EAR), administered by the Bureau of Industry and Security (BIS), and the International Traffic in Arms Regulations (ITAR), administered by the Department of State. Technologies related to defence, dual-use applications, semiconductor manufacturing, advanced computing, and certain chemical processes are subject to licensing requirements before they can be shared with foreign persons – even within the US. As Finnegan IP’s analysis points out, failure to obtain the required export licence from BIS can result in serious civil penalties, and violations are enforced under a strict liability standard.

Importantly, a patent’s public disclosure does not automatically exempt the underlying know-how from export controls. Morgan Lewis’s guidance makes clear that a foreign filing licence from the USPTO is a limited right – it covers the patent application itself but does not extend to the transfer of related technical data that may be separately controlled under EAR or ITAR. Indian licensors sharing technical documentation, training materials, or process data with US-based licensees must conduct a classification review of that information before transfer.

Choosing the right licensing structure 🔗

Once patents are secured and export control considerations are addressed, the next decision is what kind of licence to offer. The three primary models are:

Exclusive licence: Only one licensee can use the patented technology in the agreed territory. This typically commands the highest royalty rate and upfront fees, since the licensee has sole market access. However, it limits the licensor’s ability to expand to other clients in that market.

Non-exclusive licence: Multiple licensees can use the technology simultaneously. This broadens revenue streams but may lower individual royalty rates. Reserve Bank of India data on foreign collaborations indicates that exclusive licensing arrangements in foreign technical collaborations have historically been limited, generally ranging between 23% to 38% of agreements reviewed.

Sub-licensing: The primary licensee is permitted to further license the technology to third parties. This can accelerate market penetration but requires careful drafting to avoid loss of control over how the technology is used downstream.

The choice of structure should align with the licensor’s commercial strategy: maximum revenue per client versus wider market adoption versus maintaining operational control over the technology.

Structuring royalties and key contractual terms 🔗

Royalty negotiation is central to any licensing deal. Industry benchmarks show that patent licensing royalty rates typically range from 0.1% to 25% of net sales, depending on the sector, patent strength, and exclusivity terms. Pharmaceuticals and biotechnology tend to command higher rates, while manufacturing technology and industrial processes generally sit at the lower end.

A widely referenced starting point in negotiations has historically been the 25% rule, under which the licensor receives approximately 25% of the licensee’s expected profit attributable to the patented technology. However, as noted in royalty rate scholarship, US courts have moved away from treating this as a fixed formula, viewing it as a flexible baseline rather than a definitive standard.

Beyond the royalty rate itself, a well-structured licensing agreement must address several key provisions. The agreement should precisely define the scope of the licence (what the licensee can do – manufacture, sell, import, sub-license), the licensed territory, the duration, and conditions for renewal or termination. Payment mechanics matter too: whether royalties are paid as a running percentage of net sales, a lump sum, milestone-based payments, or a combination of these.

Confidentiality clauses are particularly important when know-how is involved. Unlike a patent, which is publicly disclosed, know-how is protected primarily through contractual secrecy obligations. Research on foreign technical collaborations in India shows that licensors routinely include strict confidentiality clauses that prevent licensees from disclosing technical specifications, designs, and manufacturing data to any unauthorised third party.

In India, under Section 69 of the Patents Act, 1970, a patent licence agreement should be registered with the Controller of Patents to be admissible as evidence in legal proceedings. This step is not always mandatory, but it is good practice and provides a clear evidentiary trail if disputes arise.

Partnering with local entities to facilitate entry 🔗

One practical strategy for Indian licensors entering developed markets is to partner with a local entity in the target country. A local partner – whether a distributor, joint venture company, or sub-licensor – can handle regulatory submissions, client interactions, and compliance with domestic laws, while the Indian licensor retains ownership of the underlying IP.

The Department of Scientific and Industrial Research (DSIR) under India’s government has historically supported such international technology transfer through its International Technology Transfer Programme (ITTP), facilitating joint ventures, technology licensing, and MoUs between Indian and foreign entities. Similarly, the Department of Atomic Energy (DAE) has licensed know-how from its own R&D units to both domestic and international entities for over four decades – a model that demonstrates how structured partnerships can reduce barriers to market entry.

Joint ventures deserve special mention. They allow the Indian licensor to participate in the commercial upside of the technology in the target market, rather than simply collecting royalties. The trade-off is greater complexity in governance and profit-sharing arrangements.

Navigating regulatory standards in developed markets 🔗

Developed countries impose stringent quality and regulatory standards before patented technologies can be commercialised. A pharmaceutical know-how licence for the US market, for example, requires compliance with FDA regulations. A manufacturing process technology licence for the EU must meet CE marking and relevant technical standards. Software-based inventions may be subject to data protection regulations like the GDPR.

The licensor must be prepared to demonstrate that the licensed technology can meet these standards – not just that it is patented. Due diligence by the prospective licensee will scrutinise regulatory clearances, technical documentation, and quality systems. Technology transfer agreements in the pharmaceutical sector, for example, involve detailed documentation covering all stages of development, manufacturing, and quality control. Indian licensors should prepare comprehensive technical dossiers in anticipation of this scrutiny.

Anticompetitive restrictions: what to avoid 🔗

Both Indian and foreign competition laws place limits on what a licensor can demand in a licensing agreement. Under Section 3(5) of India’s Competition Act, 2002, a patent owner can impose reasonable conditions to protect their rights, but certain practices are prohibited – such as requiring the licensee to purchase unrelated products from the licensor (tie-in arrangements), fixing the price at which the licensee sells the licensed product, or preventing the licensee from challenging the validity of the IP rights. Developed country jurisdictions have their own equivalent antitrust safeguards. A licensing agreement that falls foul of competition law in the licensee’s country can be void or expose both parties to regulatory penalties.

Putting it all together: a practical checklist 🔗

For an Indian innovator or company preparing to license patented know-how to a developed country client, the key steps are: securing patents in the target jurisdiction through PCT or direct national filings; obtaining a Foreign Filing Licence from the Indian Patent Office; conducting an export control classification review of technical data to be transferred; deciding on licence structure (exclusive, non-exclusive, or sub-licence); negotiating royalty rates and payment terms benchmarked against industry standards; drafting a comprehensive licence agreement with scope, territory, duration, confidentiality, and termination provisions clearly defined; registering the licence with the Indian Patent Office under Section 69; and, where appropriate, identifying a local partner in the target market to handle regulatory and commercial execution on the ground.

What do you think? As Indian technology companies increasingly generate world-class IP in sectors like pharmaceuticals, clean energy, and semiconductors, should Indian patent law be further amended to better support outbound licensing to developed markets – and if so, in what specific ways? And given the complexity of export control compliance, do you think Indian innovators are adequately informed about the regulatory risks of sharing technical know-how with foreign clients?

References

1. https://www.mondaq.com/india/patent/1481930/transferring-technology-and-licensing
2. https://www.iiprd.com/the-role-of-ip-licensing-in-technology-transfer-and-innovation/
3. https://www.globalpatentfiling.com/blog/-Unlocking-Innovation-Patent-Licensing-in-India
4. https://www.lexology.com/library/detail.aspx?g=55338093-cd8d-4789-a826-1e9a8d2177d7
5. https://www.trade.gov/us-export-controls
6. https://www.finnegan.com/en/insights/articles/common-myth-and-misperceptions-about-export-control-laws.html
7. https://www.morganlewis.com/-/media/files/publication/outside-publication/article/law360_whenipfallsunderexportcontrolregime_24feb14.pdf
8. https://isid.org.in/wp-content/uploads/2022/07/WP231.pdf
9. https://www.upcounsel.com/patent-licensing-royalty-rates
10. https://www.lexology.com/library/detail.aspx?g=5ed6a7c9-a712-490d-8647-723a76722cf1
11. https://www.dsir.gov.in/international-technology-transfer-programme-ittp
12. https://dae.gov.in/dae-technology-transfer-activities/
13. https://www.indialawoffices.com/legal-articles/licensing-agreement-for-technology-transfer-indian-pharma
14. https://ksandk.com/information-technology/technology-transfer-regulations-in-india/